What Are the Real Downsides of Wegovy?

You've heard about the side effects, here's what they actually look like day to day

Imagine starting your first week on Wegovy. A few hours after the injection, you feel off. Not dramatically ill, but queasy enough to wish you'd eaten less beforehand. That is the experience many people describe, and it is the most documented downside in the clinical data. In the STEP 1 trial, published in the New England Journal of Medicine, gastrointestinal events were the most common adverse effects among participants taking semaglutide 2.4mg.

The usual list includes nausea, vomiting, diarrhoea, constipation, acid reflux, burping and fatigue. These tend to peak after starting treatment or after each dose step up, then settle over a week or two for most people. For some, they persist longer. A smaller number find the side effects severe enough to stop treatment altogether. That's not a failure, it's the medicine not being right for that person.

There are rarer but more serious risks to know about. In January 2026, the MHRA issued a Drug Safety Update for GLP-1 receptor agonists flagging acute pancreatitis as an infrequent but serious risk. The signal to act on: severe stomach pain that doesn't ease, possibly spreading to the back, with or without vomiting. That warrants urgent medical attention, not a wait-and-see approach. Gallbladder problems, allergic reactions and, in people taking medicines for diabetes, low blood sugar are also documented. The NHS semaglutide medicines page lists these in full, and the patient information leaflet that comes with your pen goes further.

For many people, the side effects are manageable. For some, they're a reason to stop. If you want a fuller picture before you commit, our page covering the downsides of Wegovy sets out what the realistic experience looks like, which is more useful than discovering them after you've started.

The downsides that go beyond the gut

Side effects get most of the attention, but the practical limitations of Wegovy deserve equal space. First: it requires ongoing use to sustain results. Studies following people after they stop semaglutide show that a significant proportion of lost weight returns within a year or two. This is not a character flaw or a failure of willpower, it reflects how the medicine works and how the body responds to its absence. Anyone thinking of Wegovy as a short course should factor this in early.

Second: oral contraceptives. For women using the pill, there is nuance worth understanding. Because Wegovy slows gastric emptying, absorption of orally taken medicines can be affected. NHS guidance specifically notes that women on tirzepatide (Mounjaro) should use an additional contraceptive method during the early weeks of treatment and after dose increases; semaglutide has a different profile here, but the broader conversation about contraception and GLP-1 medicines is one to have with your prescriber. Separately, NHS England advises anyone on a GLP-1 medicine to inform their anaesthetist before any surgical procedure.

Third: who can't take it at all. Wegovy is not suitable during pregnancy, breastfeeding or when actively trying to conceive. It is not licensed for anyone under 18. People with a history of pancreatitis, medullary thyroid carcinoma or certain other conditions need careful prescriber review before considering it. These aren't small print, they matter.

If you're thinking about what the dark side of semaglutide might look like beyond the standard side-effect list, our dedicated page on that topic goes into more depth on the psychological and physiological risks that are less widely discussed.

Cost, access and the limits of the evidence

Wegovy is not available free to most people in the UK right now. NHS access exists but it is tightly restricted: NICE's guidance (TA875) limits it to specialist weight management services, requires a weight-related comorbidity, a BMI of 35 or above (lower for some ethnic backgrounds), and caps use at a maximum of two years. Waiting lists for those services are long in most areas. For people who don't meet the NHS criteria or can't wait, private prescription is the realistic route.

Private costs vary. Understanding what the price of treatment actually includes, and what it often leaves out, is worth doing before you commit. Our Wegovy price guide breaks this down clearly, covering what typical private pricing looks like and what to check for.

There is also a limitation in the evidence base itself. Wegovy's weight-loss trials ran for 68 to 72 weeks. That is long enough to give meaningful data, but many people will be on treatment for longer. The very long-term picture (beyond two years, at real-world doses, in diverse populations) is still being built. That isn't a reason to avoid the medicine; it is a reason to stay in an ongoing prescriber relationship rather than treating it as something you manage alone.

For a broader look at how Wegovy compares to other options and what it is in the first place, our overview of what Wegovy is covers the licensing, mechanism and trial background, and our semaglutide hub maps the wider picture including how it relates to Ozempic and oral semaglutide. If you're still weighing up whether it's right for you, the cons of Wegovy page looks at the trade-offs from a different angle.

A conversation with a prescriber is the only way to know whether the downsides apply to your specific situation, or whether they're outweighed by the potential benefit. If you'd like that conversation, you can start your free consultation with our team today.